Radiopharmaceutical Supply – Xofigo® (Radium Ra 223 Dichloride)

The contract involves the supply of 1,270 units of Xofigo®, a radiopharmaceutical used in the treatment of metastatic prostate cancer, with strict requirements for manufacturing, labeling, and distribution to meet FDA regulations and nuclear regulatory standards. All aspects of production and handling must comply with federal guidelines for radioactive materials, ensuring safety, efficacy, and traceability throughout the supply chain. The product is intended for use by the Department of Veterans Affairs, specifically through the 257-NETWORK Contract Office 17, indicating this is a specialized procurement focused on delivering critical medical treatments to veteran populations. The solicitation was posted on July 23, 2026, with a response deadline of July 28, 2026, at 7:00 PM, indicating a tightly managed procurement timeline. This is classified as a subcontract, suggesting it connects to a broader federal supply agreement, likely within a pre-established network of providers qualified to handle radiopharmaceuticals. The NAICS code 325412 confirms the activity falls under pharmaceutical preparation manufacturing, underscoring the high level of technical and regulatory expertise required. There is no set-aside designation, meaning all qualified vendors may bid, but the nature of the product necessitates specialized licensing, certified facilities, and proven experience in nuclear medicine logistics.